Perletti G. Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. Arch Ital Urol Androl [Internet]. 2016 Mar. 31 [cited 2024 Apr. 26];88(1):74-5. Available from: https://www.pagepressjournals.org/aiua/article/view/aiua.2016.1.74